top of page
Search

AZ cuts late-stage IL-23 drug due to trial delays, competitive landscape

  • Songsong CaO
  • Aug 8, 2023
  • 1 min read

Smart move, but could've been done earlier. It highlights two things:


1. There's always a tendency to keep a program alive for too long, even at an experienced drug developer at AZ. Fortunately with AZ-sized budget, it's just another tough break, but for startups dragging your feet to kill a program that has no differentiation could mean bankruptcy


2. Recruitment is just really tough in IBD, especially when you already have some effective drugs in the same class



 
 
 

Comentários


bottom of page